Estradiol enantate
- PDF / 183,571 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 64 Downloads / 195 Views
1
★S
First report of prolactinoma, in a transsexual patient: case report A 42-year-old male-to-female transgender patient had been receiving estrogen therapy since the age of 17 years, and was currently receiving IM estradiol enantate 10mg every 15 days [duration of therapy not stated]. On presentation for hormone treatment, elevated prolactin level of 346 ng/mL and suppressed levels of luteinising hormone (LH) and follicle stimulating hormone were noted. MRI revealed a sellar lesion with hyperintense T1 and T2 signals. He was diagnosed with prolactinoma and treated with cabergoline; estrogen therapy was continued. Five months later his prolactin level had decreased to 0.3 ng/mL and his LH and FSH levels had increased. Author comment: "This is the sixth reported case of prolactinoma in [male-to-female] transsexuals, suggesting the possible role of estrogen on prolactinoma tumorigenesis." Camara VL, et al. Estrogen as a Presumed Risk Factor for Prolactinoma in a Maleto-Female Transsexual Patient. 92nd Annual Meeting of the Endocrine Society : abstr. P1-288, 19 Jun 2010. Available from: URL: http://www.endo-society.org 803027848 Brazil
»
Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of prolactinoma associated with estradiol enantate. The WHO ADR database contained no reports of prolactinoma associated with estradiol enantate or estradiol.
0114-9954/10/1311-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 24 Jul 2010 No. 1311
Data Loading...
